[go: up one dir, main page]

WO1999022725A1 - Procede de modification de la vitesse de croissance, de l'indice de consommation et de la composition corporelle des animaux domestiques - Google Patents

Procede de modification de la vitesse de croissance, de l'indice de consommation et de la composition corporelle des animaux domestiques Download PDF

Info

Publication number
WO1999022725A1
WO1999022725A1 PCT/US1998/023518 US9823518W WO9922725A1 WO 1999022725 A1 WO1999022725 A1 WO 1999022725A1 US 9823518 W US9823518 W US 9823518W WO 9922725 A1 WO9922725 A1 WO 9922725A1
Authority
WO
WIPO (PCT)
Prior art keywords
dopa
animal
drug
effective amount
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/023518
Other languages
English (en)
Inventor
John M. Wilson
Albert H. Meier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyncron Corp
Original Assignee
Cyncron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyncron Corp filed Critical Cyncron Corp
Priority to AU13813/99A priority Critical patent/AU1381399A/en
Publication of WO1999022725A1 publication Critical patent/WO1999022725A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Definitions

  • Another object of the present invention is to provide a method of reducing the saturated/unsaturated fatty acid ratio in the muscle tissue of domestic animals by administering an effective amount of L-DOPA, a drug that increases the amount of L-DOPA in an animal's bloodstream, or a combination thereof.
  • Another object of the present invention is to provide a method for reducing total fat content of domestic animals by administering an effective amount of L-DOPA, a drug that increases the amount of L-DOPA in an animal's bloodstream, or a combination thereof.
  • the method comprises elevating the level of the amino acid L-Dihydroxyphenylalanine (L-DOPA) in the bloodstream of the domestic animal by administering an effective amount of L-DOPA, a drug that increases the amount of L-DOPA in an animal's bloodstream, or a combination thereof, so as to achieve the desired alteration in body content, growth rate, feed efficiency, or any combination thereof.
  • L-DOPA amino acid L-Dihydroxyphenylalanine
  • L-DOPA amino acid L-Dihydroxyphenylalanine
  • L-DOPA is intended to include molecules containing substitutions in the chemical formula of L-DOPA not affecting the chemical activity and efficacy of the L-DOPA molecule in this application.
  • An effective amount is intended to mean a quantity of L- DOPA which, when administered to a domestic animal, will cause the muscle tissue of that animal to have a noticeable reduction of either the saturated fatty acid content, the ratio of saturated to unsaturated fatty acids, the total fat content of the animal, or an increase in feed efficiency. Reduction of the saturated fatty acid and fat contents and a reduction of the ratio of saturated to unsaturated fatty acids are significant benefits to the meat-consuming public. The increase in the feed efficiency provided by the methods of the present invention are of significant benefit to the producers of domestic animals, as greater amounts of meat can be obtained from such animals at less cost.
  • feed efficiency is defined as the ratio of the weight of feed necessary to achieve one weight unit of body weight in a domestic animal. For example, using the weight unit “pounds”, a feed efficiency of 1 .8 would mean that it required 1 .8 pounds of feed in order to effect a 1 pound body weight gain in a domestic animal.
  • An "adult” domestic animal refers to a domestic animal capable of breeding.
  • the rates and amounts at which the L-DOPA can be administered to domestic animals to alter their body composition according to the methods of the invention may be varied. Additionally, one skilled in the art can vary the methods of administration to achieve optimum results.
  • the preferred dosage of L-DOPA is from between about 40 and about 300 mg/kg of body weight per day, preferably from about 40 to 1 50 mg/kg of body weight per day.
  • the invention lies in the discovery that elevating L-DOPA in the bloodstream of domestic animals has the effect of reducing fatty acid and fat content and saturated to unsaturated fat ratios in the muscle tissue of the domestic animals. Further, elevation of L-DOPA in the bloodstream of domestic animals increases the feed efficiency and growth rates of the animals.
  • L-DOPA can be administered to domestic animals, other than by addition to feed. For example, one could administer conventional injections of the L-DOPA to the animals. One could also administer timed-release subcutaneous implants or injections of L-DOPA.
  • L-DOPA in the Examples described herein was administered orally with animal feed, which is the preferred method of administration, the beneficial effects are believed to be derived from an elevated L-DOPA level in the bloodstream of the animals.
  • drugs which inhibit the degradation of L-DOPA may also be administered and achieve the same effect.
  • dopa decarboxylase inhibitors are carbidopa and benserazide, both of which have been used in conjunction with L-DOPA in the treatment of Parkinson's disease.
  • These inhibitors may also be administered orally, in the food of domestic animals, or by implant or injection, as described above for L-DOPA.
  • the amount of L-DOPA required to be administered can be reduced or eliminated resulting in a substantial economic savings.
  • food containing naturally occurring L- DOPA or drugs which stimulate L-DOPA synthesis may be administered to the domestic animals.
  • Drugs which stimulate L-DOPA synthesis include, but are not limited to, tyrosine, phenylalanine, and inhibitors of the enzyme dopamine beta hydroxylase such as fusaric acid, disulfiram, and cysteamine or pantethine and their derivatives.
  • Such derivatives include, without limitation, phosphocysteamine, pantetheine, 3-pyridineacetic acid and 3-(3- pyridylmethoxycarbonyD-propionic acid esters of pantethine and pantetheine, and pantetheine-4'-phosphate.
  • These agents can also be administered by conventional injection or by time-release subcutaneous implant or injection.
  • Preferred dosages of such L-DOPA stimulating agents are from between about 50 and 500 mg/kg of body weight per day, preferably between about 1 00 and 200 mg/kg of body weight per day.
  • the present invention is intended to include any method by which the level of L-DOPA in domestic animals may be artificially elevated in order to produce meat having a lower saturated fatty acid and fat level and a reduced ratio of saturated to unsaturated fatty acids. It is also intended to include any method by which the level of L-DOPA in domestic animals may be artificially elevated in order to increase the animal's growth rate or feed efficiency, relative to animals which are not being administered L-DOPA. Administration of combinations of L-DOPA and other drugs which elevate the level of L-DOPA in the bloodstream of domestic animals are also within the scope of the present invention.
  • White Leghorn layer hens were fed standard layer diets supplemented with either L-DOPA (50 mg/kg body weight) or a combination of L-DOPA (50 mg/kg) and Cysteamine (230 mg/kg) for 7 weeks. At the end of the treatment period, 1 5 were sacrificed (5/group) and breast muscle samples obtained for fatty acid analysis.
  • L-DOPA 50 mg/kg body weight
  • Cysteamine 230 mg/kg
  • Layer hens were treated at 48 weeks of age with either L-DOPA only (50 or 1 00 mg/kg body weight), cysteamine only (230 mg/kg body weight), or a combination of L-DOPA and cysteamine (50 mg/kg and 230 mg/kg respectively) for 7 weeks. Hens were sacrificed and abdominal fat dissected and weighed.
  • a Denotes a value that is significantly different from control group (P ⁇ 0.05)
  • ⁇ Denotes the average of all measurements ⁇ standard error * At this level of cysteamine, the animals stopped eating * * Female animals were sampled in this treatment group; abdominal fat data from females is omitted.
  • the average body weight of all of the broilers which were given L-DOPA, cysteamine, or a combination were evaluated weekly until day 56.
  • the average body weight for each treatment group at each measurement is shown in Table 4.
  • L-DOPA at 1 00 mg/kg and L-DOPA at 1 00 mg/kg plus 1 00 mg/kg cysteamine increased the feed efficiency of the broiler chickens.
  • L-DOPA 50, 1 00, and 200 mg/kg body weight
  • L-DOPA + cysteamine L-DOPA 50 mg/kg + cysteamine 230 or 400 mg/kg
  • cysteamine only 230 mg/kg or 400 mg/kg
  • the above described studies and method of the invention were done on poultry, one kind of domestic animal.
  • the current invention is applicable to all domestic animals which produce meat for consumption by humans.
  • the method could be used to reduce the fat content and saturated/unsaturated fatty acid ratio in the muscle tissue of beef cattle or swine, or to increase the growth rate and/or feed efficiency of such animals prior to slaughter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé permettant de réduire la quantité d'acides gras saturés, de réduire le rapport entre les acides gras saturés et les acides gras insaturés dans les tissus musculaires, de diminuer la quantité de graisse totale, et d'accroître la vitesse de croissance et l'indice de consommation chez les animaux domestiques. Ce procédé consiste à augmenter le niveau de l'acide aminé L-Dihydroxyphénylalanine (L-DOPA) dans la circulation sanguine de l'animal domestique, de manière à réaliser les modifications désirées dans la composition corporelle et/ou dans l'indice de consommation.
PCT/US1998/023518 1997-10-31 1998-10-30 Procede de modification de la vitesse de croissance, de l'indice de consommation et de la composition corporelle des animaux domestiques Ceased WO1999022725A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13813/99A AU1381399A (en) 1997-10-31 1998-10-30 Method for modifying the growth rate, feed efficiency and body composition of domestic animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6393097P 1997-10-31 1997-10-31
US60/063,930 1997-10-31

Publications (1)

Publication Number Publication Date
WO1999022725A1 true WO1999022725A1 (fr) 1999-05-14

Family

ID=22052431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023518 Ceased WO1999022725A1 (fr) 1997-10-31 1998-10-30 Procede de modification de la vitesse de croissance, de l'indice de consommation et de la composition corporelle des animaux domestiques

Country Status (2)

Country Link
AU (1) AU1381399A (fr)
WO (1) WO1999022725A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711897A (en) * 1985-04-24 1987-12-08 Smithkline Beckman Corporation Animal feed methods and compositions using cysteamine
US5665375A (en) * 1995-05-31 1997-09-09 Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of altering the contents of eggs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711897A (en) * 1985-04-24 1987-12-08 Smithkline Beckman Corporation Animal feed methods and compositions using cysteamine
US5665375A (en) * 1995-05-31 1997-09-09 Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of altering the contents of eggs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 122:313533, XP002916177 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 84:120174, XP002916174 *
DATABASE WPI 1 January 1900 Derwent World Patents Index; AN 84-01071, XP002916175, GREIF Z, ET AL: "Growth Enhancement Induced by Prolonged L-Dopa Administration in Rats" *
DATABASE WPI 1 January 1900 Derwent World Patents Index; AN 90-08478, XP002916176, LANES R, ET AL: "Effect of Chronic L-Dopa Administration on Linear Growth and GH Secretion in Healthy Prepubertal Short Children" *

Also Published As

Publication number Publication date
AU1381399A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
CA2569269C (fr) Acide guanidinoacetique servant de complement pour aliments destines aux animaux
AP387A (en) Therapeutical uses of L-methionine and compositions thereof.
JPH08505775A (ja) 動物の飼料変換効率を増加させる方法
AU771921B2 (en) Method for selectively altering body fat level, feed efficiency, or weight gain
US5665375A (en) Method of altering the contents of eggs
KR20010000198A (ko) 옻사료의 제조 및 이를 급이 사육한 옻닭과 옻란의생산방법.
KR20020060199A (ko) 동물의 비육 촉진제 및 비육 촉진 방법
JPH11514205A (ja) 有用な動物のストレス抵抗性および免疫の改善のための飼料もしくは飲料水の添加剤
EP0390783A1 (fr) Procede d'amelioration du taux de conversion alimentaire d'animaux producteurs de viande par administration par voie orale de 2-desoxy-d-hexose
RU2230523C2 (ru) Способ повышения продуктивности и неспецифической резистентности телят
WO1999022725A1 (fr) Procede de modification de la vitesse de croissance, de l'indice de consommation et de la composition corporelle des animaux domestiques
RU2826308C1 (ru) Способ повышения продуктивности цыплят-бройлеров путём снижения оксидативного стресса
US6509375B1 (en) Method for increasing productivity in breeder hens
Mustin et al. Dietary protein concentration and daily feed allowance influence response of channel catfish, Ictalurus punctatus (Rafinesque), to ractopamine
HU204696B (en) Process for producing ractopamin growth hormone combination
Radcliffe et al. Effect of cysteine ethyl ester supplements on wool growth rate
SI22407A (sl) Uporaba koencima q10 za uäśinkovitejĺ o vzrejo ĺ˝ivali in pridelavo ĺ˝ivalskih tkiv s poveäśano vsebnostjo tega koencima
RU2851818C2 (ru) Кормовой концентрат
RU2774770C1 (ru) Способ повышения привесов при одновременной профилактике оксидативного стресса у цыплят-бройлеров
EP2849577A1 (fr) Procédé permettant d'accroître les performances dans l'élevage industriel des poulets
Abbas Valine in Broiler Diets: A Review
KOBAYASHI et al. Effects of Dietary Urea, Urease and Antiurease Supplementation on Nitrogen Balance and Excretion of Urinary Nirogenous Compounds in Cockerels
Leontowicz et al. The depressant effect of ammonium acetate in the diet on the insulin level in the plasma of rats
KR20030030409A (ko) 계육내 타우린 성분 함유량 극대화 방법
JPH0525859B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA